NASDAQ:AWH - Aspira Women's Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.33
  • Forecasted Upside: 92.74 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.88
▲ +0.19 (3.34%)
1 month | 3 months | 12 months
Get New Aspira Women's Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AWH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AWH

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.33
▲ +92.74% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Aspira Women's Health in the last 3 months. The average price target is $11.33, with a high forecast of $12.00 and a low forecast of $10.00. The average price target represents a 92.74% upside from the last price of $5.88.
Buy
The current consensus among 6 investment analysts is to buy stock in Aspira Women's Health.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/29/2021Truist SecuritiesInitiated CoverageBuy$12.00N/A
i
3/29/2021TruistInitiated CoverageBuy$12.00High
i
1/28/2021Cantor FitzgeraldInitiated CoverageOverweight$10.00High
i
Rating by K. Mikson at Cantor Fitzgerald
10/31/2020MacquarieReiterated RatingHoldLow
i
10/30/2020MacquarieReiterated RatingHoldLow
i
10/30/2020William BlairReiterated RatingOutperformHigh
i
Rating by B. Weinstein at William Blair
10/29/2020William BlairInitiated CoverageOutperformHigh
i
10/14/2020Brookline Capital ManagementReiterated RatingBuyHigh
i
Rating by S. Yanchus at Brookline Capital Management
(Data available from 4/21/2016 forward)
Aspira Women's Health logo
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. It provides OVA1, Overa, and Ova1PLUS to detect the risk of ovarian malignancy. The company also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, it owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, the company is developing diagnostic algorithms; and a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. It has entered into a collaborative research agreement with Baylor Genetics to co-develop a novel ovarian cancer early-detection test; and an agreement with Dana Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer. The company has a strategic alliance with Quest Diagnostics, Incorporated. It serves physician office and hospital laboratories, as well as physicians. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $5.88
$5.68
$5.92

50 Day Range

MA: $6.87
$5.91
$8.40

52 Week Range

Now: $5.88
$1.17
$10.54

Volume

6,051 shs

Average Volume

829,063 shs

Market Capitalization

$656.90 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Aspira Women's Health?

The following Wall Street research analysts have issued research reports on Aspira Women's Health in the last year: Brookline Capital Management, Cantor Fitzgerald, Macquarie, Truist, Truist Securities, William Blair, and Zacks Investment Research.
View the latest analyst ratings for AWH.

What is the current price target for Aspira Women's Health?

3 Wall Street analysts have set twelve-month price targets for Aspira Women's Health in the last year. Their average twelve-month price target is $11.33, suggesting a possible upside of 92.7%. Truist has the highest price target set, predicting AWH will reach $12.00 in the next twelve months. Cantor Fitzgerald has the lowest price target set, forecasting a price of $10.00 for Aspira Women's Health in the next year.
View the latest price targets for AWH.

What is the current consensus analyst rating for Aspira Women's Health?

Aspira Women's Health currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AWH will outperform the market and that investors should add to their positions of Aspira Women's Health.
View the latest ratings for AWH.

What other companies compete with Aspira Women's Health?

How do I contact Aspira Women's Health's investor relations team?

Aspira Women's Health's physical mailing address is 12117 BEE CAVES ROAD BUILDING THREE SUITE 100, AUSTIN TX, 78738. The company's listed phone number is 512-519-0400 and its investor relations email address is [email protected] The official website for Aspira Women's Health is www.aspirawh.com.